The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Advanced Soft Tissue Sarcomas

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for advanced soft tissue sarcomas.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 6
Maximum Age: 80
Healthy Volunteers: f
View:

• Pathological and clinical diagnosis of advanced soft tissue sarcomas, pathological types include: fibrosarcoma, liposarcoma, undifferentiated pleomorphic sarcoma, epithelioid sarcoma, rhabdomyosarcoma, synovial sarcoma, alveolar soft-part sarcoma, leiomyosarcoma, clear cell sarcoma, malignant schwannoma, angiosarcoma.

• Consider immunotherapy or combined immunotherapy based on clinical judgement.

• Signed and dated informed consent form.

• Commitment to comply with research procedures and co-operation in the implementation of the full research process.

• Aged 6-80 years old.

Locations
Other Locations
China
Ruijin Hospital affiliated to Shanghai Jiao Tong University of Medicine
RECRUITING
Shanghai
Contact Information
Primary
Jiajia Hu
jiajiahu@shsmu.edu.cn
13524945287
Time Frame
Start Date: 2024-10-15
Estimated Completion Date: 2027-07-31
Participants
Target number of participants: 40
Treatments
Diagnosis of advanced soft tissue sarcomas
Patients diagnosis of advanced soft tissue sarcomas require immunotherapy or combination immunotherapy after evaluation
Related Therapeutic Areas
Sponsors
Leads: Ruijin Hospital

This content was sourced from clinicaltrials.gov